## Appendix A \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Parameter** & \multicolumn{2}{c}{**Univariate Analysis (N = 344)**} & \multicolumn{2}{c}{**Multivariate Analysis (N = 286)**} \\ \hline  & _n (\%)_ & **HR (95\% CI)** & _n (\%)_ & **HR (95\% CI)** \\ \hline DRd treatment line & & & & \\
1L & 208 (60.5) & Ref & 208 (72.7) & Ref \\
2L & 78 (22.7) & 1.52 (0.64, 3.60) & 78 (27.3) & 1.56 (0.65, 3.75) \\ \(\geq\)3L & 58 (16.9) & 1.66 (0.71, 3.88) & - & - \\ Sex & & & & \\ Male & 181 (52.6) & Ref & 148 (51.7) & Ref \\ Female & 163 (47.4) & 1.25 (0.69, 2.27) & 138 (48.3) & 1.30 (0.57, 2.99) \\ Age & & & & \\ \(<\)75 years & 152 (44.2) & Ref & 118 (41.3) & Ref \\ \(\geq\)75 years & 192 (55.8) & 1.10 (0.61, 1.99) & 168 (58.7) & 0.86 (0.38, 1.97) \\ CCI category \({}^{\text{a}}\) & & & & \\ Low & 124 (36.0) & Ref & 103 (36.0) & Ref \\ Medium/high/very high & 220 (64.0) & 0.89 (0.48, 1.63) & 183 (64.0) & 0.66 (0.22, 2.04) \\ Comorbidities \({}^{\text{b}}\) & & & & \\ Congestive & 70 (20.3) & 0.75 (0.33, 1.68) & 57 (19.9) & 0.69 (0.19, 2.54) \\ heart failure & & & & \\ Renal disease & 58 (16.9) & 0.86 (0.36, 2.04) & 51 (17.8) & 1.51 (0.47, 4.81) \\ Diabetes & & & & \\ Without chronic & & & & \\ complications & 41 (11.9) & 1.83 (0.85, 3.96) & 35 (12.2) & 1.97 (0.51, 7.55) \\ With chronic & & & & \\ complications & 11 (3.2) & 0.59 (0.08, 4.28) & 9 (3.1) & 1.35 (0.16, 11.48) \\ Cerebrovascular & & & & \\ disease & 45 (13.1) & 1.40 (0.62, 3.16) & - & - \\ \hline \hline \end{tabular}
\end{table} 
Table 10: Univariate and multivariate analyses of factors associated with overall survival from the time of multiple myeloma diagnosis. \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Parameter** & \multicolumn{2}{c}{**Univariate Analysis (N = 323)**} & \multicolumn{2}{c}{**Multivariate Analysis (N = 272)**} \\ \hline  & _n (\%)_ & **HR (95\% CI)** & _n (\%)_ & **HR (95\% CI)** \\ \hline \multicolumn{4}{c}{DRd treatment line} \\
1L & 200 (61.9) & Ref & 200 (73.5) & Ref \\
2L & 72 (22.3) & 1.34 (0.87, 2.08) & 72 (26.5) & 1.34 (0.85, 2.12) \\ \(\geq\)3L & 51 (15.8) & 2.25 (1.44, 3.50) & - & - \\ Sex & & & \\ Male & 170 (52.6) & Ref & 140 (51.5) & Ref \\ Female & 153 (47.4) & 0.84 (0.58, 1.20) & 132 (48.5) & 0.95 (0.62, 1.45) \\ Age & & & \\ \(<\)75 years & 138 (42.7) & Ref & 109 (40.1) & Ref \\ \(\geq\)75 years & 185 (57.3) & 0.83 (0.58, 1.19) & 163 (59.9) & 0.84 (0.56, 1.28) \\ CCI category \({}^{\rm a}\) & Low & 60 (18.6) & Ref & 56 (20.6) & Ref \\ Medium/high/very & 263 (81.4) & 1.17 (0.72, 1.92) & 216 (79.4) & 1.05 (0.54, 2.04) \\ \multicolumn{4}{c}{Morphidities \({}^{\rm b}\)} \\ \multicolumn{4}{c}{Congestive heart} \\ failure & 98 (30.3) & 1.22 (0.84, 1.76) & 77 (28.3) & 1.22 (0.77, 1.95) \\ \multicolumn{4}{c}{BenaI disease} \\ Diabetes & & & \\ Without chronic & 64 (19.8) & 0.97 (0.62, 1.50) & 53 (19.5) & 0.92 (0.54, 1.58) \\ \multicolumn{4}{c}{With chronic} \\ complications & 17 (5.3) & 0.51 (0.21, 1.24) & 13 (4.8) & 0.64 (0.23, 1.76) \\ Cerebrovascular & 66 (20.4) & 0.70 (0.43, 1.13) & - & - \\ \multicolumn{4}{c}{Liver disease} \\ Mild & 53 (16.4) & 1.02 (0.64, 1.62) & 43 (15.8) & 1.08 (0.61, 1.90) \\ Moderate or severe & 1 (0.3) & 8.49 (1.16, 61.92) & - & - \\ Chronic pulmonary & 77 (23.8) & 0.94 (0.62, 1.41) & - & - \\ disease & 83 (25.7) & 1.44 (0.99, 2.10) & - & - \\ \hline \end{tabular}
\end{table} 
Table 2: Univariate and multivariate analyses of factors associated with time to next treatment from the first DRd administration (\(N=323\)). **Figure A1. ** Study design. Day 0 (date of diagnosis of MM) was considered the index date. The follow-up period was from the index date to death or the end of available data, whichever occurred first (where data were unavailable, they were censored at the date the patient was last known to be alive [for OS] or at the last recorded activity in the medical record [for TTNT]). 1L, first line; 2L, second line; \(\geq\)3L, third line or later; DRd, daratumumab + lenalidomide + dexamethasone; MM, multiple myeloma; OS, overall survival; TTNT, time to next treatment.